Skip to main content
News Geyer 11.2021
left: Prof. Matthias Geyer; right: Ines Kaltheuner
© David Fußhöller / UKB

News categories: Publication

Abemaciclib inhibits kinases involved in transcriptional regulation

Protein structures of Homeodomain-interacting protein kinase (HIPK) and dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) reveals abemaciclib as potent inhibitor

Abemaciclib is a widely used drug in the therapy of hormone-receptor positive (HR-positive) and human epidermal growth factor receptor negative (HER2-negative) advanced breast cancer. The drug functions as a direct inhibitor of cyclin-dependent kinases 4 and 6 (Cdk4/Cdk6). Both kinases are responsible for the deactivation of retinoblastoma protein (Rb) by phosphorylation. Until its deactivation, Rb prevents cell cycle progression. The defective functionality of Rb in several major cancers leads to extensive cell growth and tumor progression. Direct targeting and inactivation of Cdk4/Cdk6 by abemaciclib prevents Rb deactivation and reduces therefore oncogenic cell proliferation.

Prof. Matthias Geyer, Director of the Institute of Structural Biology and member of the Cluster of Excellence ImmunoSensation2 at the University Clinics Bonn, and his team now show that abemaciclib also acts as potent inhibitor of further kinases involved in transcriptional regulation. In collaboration with the team of Prof. Nathanael Gray from the Dana-Farber Cancer Institute at Harvard Medical School, Boston, the scientists found Homeodomain-interacting protein kinases (HIPKs) and dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) to be inhibitable by abemaciclib. Both proteins are auto-activated and supposed to directly act in transcriptional regulation, as recombinant HIPKs and DYRK1A phosphorylate the negative elongation factor SPT5, the transcription factor c-Myc, and the C-terminal domain of RNA polymerase II.

By providing crystal structures of HIPK3 and DYRK1A bound to abemaciclib respectively, Prof. Geyer and his team show that abemaciclib-binding occurs to the hinge region of the kinases. Hence, the interaction occurs in a similar mode as previously observed for Cdk4 and Cdk6. “HIPKs and DYRK1A are closely related kinases and both are targeted by abemaciclib with similar efficacy as Cdk4/6.” Prof. Geyer states.

Like Cdk4 and Cdk6, HIPKs are involved in the pathologies of various cancers, but also other conditions like diabetes type II, chronic fibrosis, Alzheimer´s and Huntington´s disease. The crystal structures of HIPK3 and DYRK1A in complex with abemaciclib provided now, add to the understanding of the mode of action of the clinically used inhibitor. “Also, this work opens up new opportunities for the structure-guided design of small-molecule compounds targeting HIPKs” adds Ines Kaltheuner, PhD Student at the Institute of Structural Biology.


Participating institutions and funding

Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, USA. This work was supported by a grant of the DFG (GE 976/9-2) and by a grant from the Deutsche Krebshilfe (70114008).


Publication

Ines H. Kaltheuner et al. (2021). Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation. Nature Communications 12:6607. https://www.nature.com/articles/s41467-021-26935-z


Contact

Prof. Matthias Geyer

Institute of Structural Biology

Biomedical Center

University of Bonn

Venusberg-Campus 1

53127 Bonn, Germany

phone: +49 228 287-51400

fax: +49 228 287-51221

e-mail: matthias.geyer@uni-bonn.de

Related news

Prof. Hartmann interviewed by Dr. Barbara Kreppel for 'Angewandte Nuklearmedizin'

News categories: Publication

Immunology and Nuclear Medicine

Prof. Gunther Hartmann was interviewed for the magazine “Angewandte Nuklearmedizin” and answered questions about immunology and nuclear medicine.
View entry
Dirk Baumjohann

News categories: Publication

New findings on the immune system

Bonn researchers decipher an underlying mechanism for the development of T follicular helper cells.
View entry
Domnica Luca AG Kato

News categories: Publication

Kato group publishes article in Science Advances

Dysregulation of regulatory T cell homeostasis by ADAR1 deficiency and chronic MDA5 signaling
View entry

Back to the news overview